CL2016001167A1 - Uso de un implante bioerosionable para tratar enfermedades oculares. - Google Patents

Uso de un implante bioerosionable para tratar enfermedades oculares.

Info

Publication number
CL2016001167A1
CL2016001167A1 CL2016001167A CL2016001167A CL2016001167A1 CL 2016001167 A1 CL2016001167 A1 CL 2016001167A1 CL 2016001167 A CL2016001167 A CL 2016001167A CL 2016001167 A CL2016001167 A CL 2016001167A CL 2016001167 A1 CL2016001167 A1 CL 2016001167A1
Authority
CL
Chile
Prior art keywords
eye diseases
bioerodible implant
treat eye
treat
implant
Prior art date
Application number
CL2016001167A
Other languages
English (en)
Inventor
Jane-Guo Shiah
Rahul Bhagat
Wendy M Blanda
Therry Nivaggioli
Lin Peng
David Chou
David A Weber
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52001114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001167(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2016001167A1 publication Critical patent/CL2016001167A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

<p>METODO PARA TRATAR EL EDEMA MACULAR DIABETICO (EMD) QUE COMPRENDE LA INYECCION DE UN IMPLANTE BIOEROSIONABLE EN EL VITREO DE UN HUMANO, QUE ADMINISTRA EN FORMA SOSTENIDA UN MEDICAMENTO.</p>
CL2016001167A 2013-11-15 2016-05-13 Uso de un implante bioerosionable para tratar enfermedades oculares. CL2016001167A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361904887P 2013-11-15 2013-11-15

Publications (1)

Publication Number Publication Date
CL2016001167A1 true CL2016001167A1 (es) 2017-01-06

Family

ID=52001114

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001167A CL2016001167A1 (es) 2013-11-15 2016-05-13 Uso de un implante bioerosionable para tratar enfermedades oculares.

Country Status (24)

Country Link
US (1) US20150140062A1 (es)
EP (2) EP3714875A1 (es)
JP (2) JP6675307B2 (es)
KR (3) KR20220082934A (es)
CN (1) CN105764517A (es)
AU (3) AU2014348369B2 (es)
CA (1) CA2929689A1 (es)
CL (1) CL2016001167A1 (es)
CY (1) CY1123344T1 (es)
DK (1) DK3068403T3 (es)
ES (1) ES2819215T3 (es)
HU (1) HUE050913T2 (es)
IL (2) IL245548A0 (es)
MX (2) MX2016006334A (es)
MY (1) MY176039A (es)
NZ (1) NZ719953A (es)
PH (1) PH12016500869B1 (es)
PL (1) PL3068403T3 (es)
PT (1) PT3068403T (es)
RU (1) RU2690841C1 (es)
SG (1) SG10201809363SA (es)
SI (1) SI3068403T1 (es)
UA (1) UA122117C2 (es)
WO (1) WO2015073895A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016297187A1 (en) * 2015-07-23 2018-02-15 Aerie Pharmaceuticals, Inc. Intravitreal drug delivery systems for the treatment of ocular conditions
WO2019226516A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
CN111989068A (zh) 2018-05-24 2020-11-24 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
ATE306951T1 (de) 2000-11-29 2005-11-15 Allergan Inc Verhinderung von transplantatabstossung im auge
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
EP2673049A4 (en) * 2011-02-11 2015-04-08 Psivida Inc METHOD FOR THE TREATMENT OF MOLECULAR SOILS WITH ANTIOTE THERAPEUTICS

Also Published As

Publication number Publication date
KR20160085847A (ko) 2016-07-18
IL245548A0 (en) 2016-06-30
CY1123344T1 (el) 2021-12-31
RU2690841C1 (ru) 2019-06-06
ES2819215T3 (es) 2021-04-15
JP2016538292A (ja) 2016-12-08
AU2014348369A1 (en) 2016-06-09
SI3068403T1 (sl) 2020-11-30
AU2022204607A1 (en) 2022-07-21
EP3714875A1 (en) 2020-09-30
WO2015073895A1 (en) 2015-05-21
JP2020055862A (ja) 2020-04-09
KR102475746B1 (ko) 2022-12-08
EP3068403A1 (en) 2016-09-21
CN105764517A (zh) 2016-07-13
MX2016006334A (es) 2016-09-06
KR20220082934A (ko) 2022-06-17
AU2020204362A1 (en) 2020-07-23
PL3068403T3 (pl) 2021-01-11
SG10201809363SA (en) 2018-11-29
HUE050913T2 (hu) 2021-01-28
PH12016500869A1 (en) 2016-07-04
EP3068403B1 (en) 2020-06-17
JP6675307B2 (ja) 2020-04-01
JP7022735B2 (ja) 2022-02-18
KR20240058976A (ko) 2024-05-07
PT3068403T (pt) 2020-09-18
DK3068403T3 (da) 2020-09-07
US20150140062A1 (en) 2015-05-21
IL290837A (en) 2022-04-01
NZ719953A (en) 2022-01-28
MY176039A (en) 2020-07-22
CA2929689A1 (en) 2015-05-21
RU2016119132A (ru) 2017-12-20
AU2014348369B2 (en) 2020-04-02
UA122117C2 (uk) 2020-09-25
MX2022002306A (es) 2022-03-25
PH12016500869B1 (en) 2016-07-04

Similar Documents

Publication Publication Date Title
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
CL2015002691A1 (es) Miostatina antagonista en sujetos humanos
CL2014002342A1 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma.
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
CY1120213T1 (el) Antαγωνιστες φθοριωμενης ιντεγκρινης
AR093490A1 (es) Formas de dosificacion de ruxolitinib de liberacion sostenida
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
EA201591679A1 (ru) Способ нетоксического лечения абстиненции, вызванной лекарственным средством
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
AR096183A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco
CL2016000436A1 (es) Método para el tratamiento de la enfermedad fibrótica
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112012028773A2 (pt) composições farmacêuticas compreendendo hidromorfona e naloxona
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.